Chapter 1 is in the form of an introduction outlining the scope of the survey. In the first section of Chapter 2 the operational capacities for 7 categories of established fermentation products are assessed by geographical region. For each region we have identified producers, product range and capacity. Fermentation companies together with their products are identified. In a final section the total worldwide fermentation capacity is summarised.

In Chapter 3, we have reviewed the current legislation in EU and U.S. concerning fermentation recombinant microbial organisms. The plant capacity for biotechnological products by region [Europe, U.S., Japan and rest of world] is given and novel biotechnology products that are likely to appear in the near future are reviewed.

In Chapter 4, fermentation and biotechnology companies in Europe, U.S., Japan and Korea are profiled. Each profile encapsulates data relating to the company's involvement in fermentation with specific reference to: sales, turnover, product range including traditional fermentation and biotechnological products. The fermentation plants including location and capacity are reviewed.

In Chapter 5, we have estimated the manufacturing cost for 13 fermentation products, Including: human insulin, a-interferon, streptokinase, penicillin G, cyclosporin A, lovastatin, vitamin B2, vitamin B12, lysine, citric acid, alkaline protease, chymosin, a-amylase

Chapter 6 is an Executive Summary highlighting the conclusions. The worldwide fermentation capacities by region, as well as the proportional capacities devoted to the different product sectors are presented by charts. Production economics for various fermentation and biotechnology products are reviewed listing yields, manufacturing costs and product output values.